Evidence map›Paper›PMID 38071346›Full record

ReviewEuropean journal of medical research2023

Mesenchymal stem cells-derived exosomes: novel carriers for nanoparticle to combat cancer.

Reza Abbasi, Raziye Momen Mesgin, Fereshteh Nazari-Khanamiri, Nima Abdyazdani, Zeynab Imani, Shabnam Pirnezhad Talatapeh, Aidin Nourmohammadi, Vahid Nejati, Jafar Rezaie

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Reza AbbasiDepartment of Biology, Urmia University, Urmia, Iran.
Raziye Momen MesginDepartment of Biology, Urmia University, Urmia, Iran.
Fereshteh Nazari-KhanamiriSolid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Shafa St, Ershad Blvd, Urmia, Iran.
Nima AbdyazdaniStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Zeynab ImaniDepartment of Biology, Urmia University, Urmia, Iran.
Shabnam Pirnezhad TalatapehDepartment of Biology, Urmia University, Urmia, Iran.
Aidin NourmohammadiStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahid Nejati *Department of Biology, Urmia University, Urmia, Iran. v.nejati@urmia.ac.ir.
Jafar Rezaie *Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Shafa St, Ershad Blvd, Urmia, Iran. Rezaie.j@umsu.ac.ir.
Urmia University · IRTabriz University of Medical Sciences · IRUrmia University of Medical Sciences

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe advancement in novel cancer therapeutics brought a platform combining the properties of exosomes with nanoparticles to precision medicine. The novel therapeutic approach aim is cancer-targeted therapy. Exosomes from mesenchymal stem cells (MSCs-Exo) exhibit unique properties in cancer therapies, which makes them an ideal tool for delivering therapeutic agents into tumor cells. The key role of natural MSCs-Exo is controversial in cancer therapy; however, they can be engineered at their surface or cargo to serve as a smart drug delivery system for cancer-targeted therapy. In the last few years, researchers harnessed nanotechnology to enforce MSCs-Exo for cancer management including, tumor cell tracking, imaging, and tumor cell killing. Different nanoparticles such as gold nanoparticles have particularly been incorporated into MSCs-Exo, which showed an efficient accumulation at the site of tumor with improved anticancer impact. These findings indicate that a hybrid of exosomes-nanoparticles may serve as combination therapy for the effective removal of cancers. SHORT

conclusionAlthough exhibiting impressive potential, the use of nanoparticle-loaded MSCs-Exo as a drug-delivery tool has been troubled by some challenges, therefore, translation to clinic prerequisites further scrutiny. In this review, we focus on nanoparticle-loaded MSCs-Exo as a new cancer therapy and discuss engineered MSC-Exo for target therapy.

Indexed as

ExosomesMesenchymal Stem CellsMetal NanoparticlesNeoplasmsGoldHumansGoldCancer therapyExosomesMesenchymal stem cellsNanoparticles

Identifiers

PMID38071346
PMCPMC10709841
OpenAlexW4389507507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.